Gilead Sciences Inc Stock Price, News & Analysis

Galapagos NV and Gilead Sciences have announced the halt of the ISABELA Phase 3 clinical studies for ziritaxestat, an investigational autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF). This decision follows the Independent Data Monitoring Committee's review, which indicated that the benefit-risk profile of ziritaxestat no longer supports ongoing trials. The ISABELA program aimed to enroll 1,500 patients, but all trials, including a Phase 2a extension, will be discontinued. Both companies expressed disappointment but remain committed to advancing IPF research.

Kite, a Gilead Company (Nasdaq: GILD), has appointed Frank Neumann, MD, PhD, as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will spearhead Kite's clinical initiatives in hematological malignancies and solid tumors. He joins from Verastem, bringing extensive experience in cell therapy and oncology. Ken Takeshita, MD, is set to leave the company at the end of February after successfully overseeing multiple clinical program milestones, including FDA approvals. Dr. Neumann is excited to expand Kite's cell therapy portfolio, aiming to deliver innovative treatments for cancer patients.

Gilead Sciences (Nasdaq: GILD) has announced a 4.4% increase in its quarterly cash dividend, raising it to $0.71 per share. This adjustment will take effect in the first quarter of 2021, with the dividend payable on March 30, 2021, to stockholders on record as of March 15, 2021. The decision reflects Gilead's ongoing commitment to returning value to shareholders, although future dividends will remain subject to approval by the Board of Directors.

Gilead Sciences (Nasdaq: GILD) announced its Q4 and full-year 2020 results, emphasizing the significant role of Veklury in treating hospitalized COVID-19 patients. CEO Daniel O’Day highlighted the company's commitment to addressing various health needs, including HIV and cancer. Gilead is optimistic about growth opportunities in oncology with Trodelvy, while continuing its leadership in antivirals. Overall, the company is positioned for growth as it enters 2021.

Gilead Sciences (Nasdaq: GILD) and Gritstone Oncology (Nasdaq: GRTS) have announced a collaboration to develop a vaccine-based immunotherapy aimed at curing human immunodeficiency virus (HIV) infection. The partnership will utilize Gritstone's prime-boost vaccine platform, combining self-amplifying mRNA and adenoviral vectors with antigens from Gilead. Gilead will initially invest $60 million, including a $30 million cash payment and a $30 million equity investment, and has the option for further funding up to $725 million based on clinical milestones.

Gilead Sciences, Inc. (Nasdaq: GILD) is set to announce its fourth quarter and full year 2020 financial results on February 4, following market close. A conference call with management will occur at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the live webcast on the company’s Investors page. Additionally, a replay will be available approximately two hours after the call until February 6. Gilead is dedicated to developing innovative medicines for serious health challenges globally.

Kite, a Gilead Company (Nasdaq: GILD), announced the appointment of Dr. Francesco Marincola as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola brings extensive experience in oncology and immunotherapy, previously serving as President and Chief Scientific Officer at Refuge Biotechnologies Inc. His leadership is expected to enhance Kite’s research in CAR T therapies. Kite focuses on innovative cancer immunotherapies, aiming to provide curative cell therapies for patients.

Gilead Sciences (NASDAQ: GILD) and Vir Biotechnology (NASDAQ: VIR) announced a clinical collaboration to explore new therapeutic combinations for chronic hepatitis B virus (HBV). A Phase 2 trial will evaluate therapies involving Gilead's selgantolimod, VIR's VIR-2218, and a PD-1 antagonist. The study aims to achieve a functional cure, defined by the loss of hepatitis B surface antigen (HBsAg) and HBV DNA. Both firms retain rights to their products and will consider future studies based on Phase 2 results. Current therapies require lifelong treatment for over 290 million HBV patients globally.